101 results about "Gastric adenocarcinoma" patented technology

The invention discloses a biomarker for gastric adenocarcinoma diagnosis. The biomarker is LINC01234. The expression level of the LINC01234 in a gastric adenocarcinoma patient is remarkably improved, and a TCGA database performs cross validation on the difference expression. The LINC01234 is subjected to ROC curve analysis to find out that the LINC01234 has a higher AUC value and higher accuracy and specificity, and to prompt that the LINC01234 can be applied to early diagnosis on gastric adenocarcinoma by serving as a potential marker.

The invention discloses marine traditional Chinese medicine gracilariopsis lemaneiformis polysaccharide derived from red alga plant gracilariopsis lemaneiformis, discloses a synergistic effect of the gracilariopsis lemaneiformis polysaccharide serving as anti-tumor drugs, especially a synergist of cis-platinum for the first time, and further discloses an application of the gracilariopsis lemaneiformis polysaccharide to preparation of drugs or healthcare products or food for treating tumors. The gracilariopsis lemaneiformis polysaccharide can serve as a synergist of the anti-tumor drugs. The anti-tumor effect is achieved mainly by retraining growth and propagation of tumor cells, and the anti-tumor effect is achieved for gastric adenocarcinoma, lung cancer and carcinoma of the uterine cervix. The invention further discloses a preparation method of the gracilariopsis lemaneiformis polysaccharide and a detection method of the anti-tumor effect of the gracilariopsis lemaneiformis polysaccharide. A new way is provided for further utilization of gracilariopsis lemaneiformis serving as marine drug resources, and a new choice is provided for development of the anti-tumor drugs for treating or preventing tumors through the application of the gracilariopsis lemaneiformis polysaccharide to preparation of the anti-tumor drugs or anti-cancer healthcare products or food.

The invention relates to a preparation method of an organic hybrid trinuclear platinum complex possessing a Y type structure synthesized by supermolecules self-assembly as well as treatment for gastric adenocarcinoma cells. The MTT experiment data shows that the compound can cross a drug resistance mechanism of cisplatin, and can specifically target to the gastric adenocarcinoma cells. A platinum ligand Pt(NH3)2Cl(NO3)] in which the chloride ion is replaced by nitrate and a bridge ligand (2,4,6-tri(pyridin-4-yl)-1,3,5-triazine) are subjected to self-assembly, thereby the novel and latent medicine for treating gastric adenocarcinoma with excellent anticancer activity and tumor targeting is obtained. Because the complex enables specific recognition of the gastric adenocarcinoma cells, and can induce the G-rich sequence of the oncogene to form a G-quadruplex structure, the activity of telomerase can be inhibited, thereby the complex possesses high gastric adenocarcinoma resistance activity. The preparation method has the advantages of simple process and low cost, can be completed in a general chemical laboratory, and the production process is environmentally-friendly. The trinuclear platinum complex possessing Y type structure can be taken as the novel and latent gastric adenocarcinoma resistance medicine.

The invention belongs to the technical field of the tumor medicine, and specifically discloses an autoantibody joint detection ELISA kit for gastric cardiac adenocarcinoma early screening. The kit comprises a solid-phase carrier and tumor-associated antigen coated on the solid-phase carrier; the tumor-associated antigen is composed of Dock10, IVL, CDH1 and P53; furthermore, the kit further comprises sample diluent, a second antibody, second antibody diluent, positive control serum, negative control serum, a developing solution, a stop solution and a washing solution. The ELISA kit disclosed bythe invention can effectively detect the gastric cardiac adenocarcinoma, especially the early gastric cardiac adenocarcinoma; the detection sensitivity is up to 87.5%, and the specificity reaches 75%; and the kit can be used for the large-scale screening of the asymptomatic population at the high incidence area of the gastric cardiac adenocarcinoma, thereby facilitating the gastric cardiac adenocarcinoma screening and early discovery of the asymptomatic high-risk group.

The invention provides a prostate-specific antigen targeting inhibitor of a nuclide marker. The targeting inhibitor is DKFZ-PSMA-617 of a radioactive nuclide marker. Radioactive nuclide includes at least one of 64Cu, 68Ga and 89Zr. The invention further provides a preparation method of the nuclide marker DKFZ-PSMA-617. The nuclide marker DKFZ-PSMA-617 is stable in property and good in development effect, has high affinity and functional activity on PSMA, is beneficial to diagnosis and accurate staging of early prostate cancer, and provides a new thought for diagnosis of breast cancer and gastric adenocarcinoma. Further preclinical animal level research proves that the inhibitor is expected to become a targeting PSMA developing agent and a tumor treatment agent with good application prospects.

The invention discloses a series of amino acid derivatives prepared by using diosgenin as a lead compound through corresponding chemical reaction. Solubility test finds that the solubility of derivatives is increased compared with the raw material medicine of diosgenin; and the pharmacological experiments prove that the diosgenin amino acid derivatives have in vitro antitumor activity, have different degrees of growth inhibition on human colon cancer cell Caco-2, human gastric carcinoma cell MGC-709, human lung adenocarcinoma cell SPC-A-1 and human neuroblastoma cell SH-SY5Y, and have anti tumor activity similar to that of a nuclear parent compound diosgenin.

The invention provides an antineoplastic traditional Chinese medicine composition, and belongs to the technical field of traditional Chinese medicine. The antineoplastic traditional Chinese medicine composition comprises an A component and a B component; the A component comprises red date, Chinese yam, semen coicis, rhizoma atractylodis macrocephalae, radix codonopsis, radix salviae miltiorrhizae,licorice root, rhizoma polygonati, radix notoginseng, fructus hordei germinatus, bulbus lilii, black rice, black soybean hull, black fungus, lotus seed, tremella fuciformis, sugar candy and garlic juice; the B component comprises ground beeltle, caulis spatholobi, spreading hedyotis herb, herba taraxaci, rhizoma curcumae, common selfheal fruit-spike, rhizoma paridis, angelica sinensis, ginseng, radix astragali, Chinese caterpillar fungus, lucid ganoderma, radix sophorae flavescentis, rhizome chuanxiong, pericarpium citri reticulatae, licorice root, calculus bovis, cortex phellodendri and honey. The provided antineoplastic traditional Chinese medicine composition can effectively resist melanoma, prostatic cancer, lung cancer, colon cancer, liver cancer, pancreatic cancer, esophagus cancer,gastric adenocarcinoma, lymphoma, breast cancer and cervical cancer.

The present invention relates to correlating high gene copy number and/or the overexpression of β-defensin 2 (“BD2”) with susceptibility to disease conditions resulting from, associated with or mediated by Helicobacter pylori infection, for example, susceptibility to peptic ulcer, non-ulcer dyspepsia, gastric cancer (e.g., gastric adenocarcinoma), and mucosa associated lymphoid tissue (MALT) lymphoma.

Provided is a gastric cancer cell line derived from a mouse deficient in E-cadherin and p53, and a use thereof. The E-cadherin- and p53-deficient, murine-derived gastric cancer cell line of the present invention was confirmed to have histopathological characteristics similar to those of human gastric cancer, have an epithelial mesenchymal transition (EMT) phenotype and an activated β-catenin pathway, and promote cancer growth in vivo due to potential of carcinogenesis, and thus the gastric cancer cell line of the present invention can be effectively used for the evaluation of the activity of new anticancer drugs and the development of metastasis inhibitors.

The invention relates to an application of a bacillus subtilis protein AMEP412 with an amino acid sequence as shown in SEQ ID NO: 1 in inhibition of tumor cell proliferation. The tumor cells are any one of liver cancer cells, cervical cancer cells, pancreatic cancer cells, colon cancer cells, prostate cancer cells, lung cancer cells, uterine squamous cell carcinoma cells, gastric adenocarcinoma cells, malignant glioblastoma cells and breast cancer cells. According to the invention, the inhibition function of the protein AMEP412 on tumor cells is found; the protein can generate an inhibition effect on 10 kinds of tumor cells, has selective specificity on inhibition effects on different kinds of tumor cells, and has the best effect on breast cancer cells; transcriptomics research finds that the protein AMEP412 can cause the change of a plurality of pathways related to apoptosis and death in tumor cells, and a new material is accumulated for inhibiting the activity of the tumor cells.

The present application describes a binding epitope to Helicobacter pylori, namely substances comprising the oligosaccharide sequence -Gal(Nac)_r2$g(b)4Glc(A)_q2(Nac)_r3-, and the use thereof in pharmaceutical and nutritional compositions for the treatment of conditions due to the presence of Helicobacter pylori in a subject, e.g. gastritis, gastric ulcers, gastric adenocarcinoma, liver disease, pancreatic disease, skin disease, heart disease, autoimmune diseases and sudden infant death syndrome. The invention is also directed to the use of the receptor for diagnostics of Helicobacter pylori, to a method of producing chondroitin oligosaccharides from chondroitin sulphates, and a method for production of amidated glucuronic acid comprising oligosaccharides and monosaccharides from glucuronic acid comprising polysaccharides.

The invention relates to new medical uses of acyl chloride and sulfonyl chloride derivatives having a general formula I structure described in the Chinese patent application (CN 200710060530.5) in aspect of anti-tumor, especially new uses of this type compounds and pharmaceutically acceptable salts or medicinal compositions thereof in preparing anti-tumor drugs. Specifically speaking, the presentinvention relates to application in treating colorectal carcinoma, leukemia, gastric adenocarcinoma, breast cancer, oral cancer, lung cancer, sarcoma and melanoma. Wherein, the definition of each group is described as the specification.

The invention belongs to the technical field of medical image processing, and particularly relates to a gastric adenocarcinoma focus segmentation method based on Swinin-Unet, which comprises a network establishment stage, a training stage and a reasoning stage. The method can solve the problems that the location of the focus is inaccurate, and clinical diagnosis and treatment are easily affected, can capture remote information, better represents local features, enables the edge segmentation effect of the gastric cancer focus to be smoother, and has a better market application prospect.

The invention discloses a molecular marker-PPM1A gene related to gastric adenocarcinoma metastasis. Through detection of the contents of PPM1A gene and expression products of the PPM1A gene in tissue of a subject, whether or not the subject suffers from gastric adenocarcinoma is judged or the subject has a risk of suffering from the gastric adenocarcinoma is diagnosed. Moreover, through study of invasion and migration indexes of gastric adenocarcinoma cells cultured in vitro, the PPM1A gene being as a drug target for curing the gastric adenocarcinoma is proved.

Helicobacter pylori is closely associated with chronic gastritis, peptic ulcer disease, and gastric adenocarcinoma. Helicobacter pylori neutrophil-activating protein (HP-NAP), a virulence factor of Helicobacter pylori, plays an important role in pathogenesis of Helicobacter pylori infection. Since HP-NAP has been proposed as a candidate vaccine against Helicobacter pylori infection, an efficient way to obtain pure HP-NAP needs to be developed. In the present invention, recombinant HP-NAP expressed in Bacillus subtilis and Escherichia coli was purified through a single step of DEAE Sephadex ion-exchange chromatography with high purity. Also, purified recombinant HP-NAP was able to stimulate neutrophils to produce reactive oxygen species. Thus, recombinant HP-NAP obtained from our Bacillus subtilis expression system and Escherichia coli expression system is functionally active. Furthermore, this one-step negative purification method should provide an efficient way to purify recombinant HP-NAP expressed in Bacillus subtilis and Escherichia coli for basic studies, vaccine development, or drug design.